

COM23-43209

Lafci G. <sup>1</sup>, Lecoutre A. <sup>1</sup>, Courtin J. <sup>1</sup>, Dezoteux F. <sup>2</sup>, Pelletier De Chambure D. <sup>3</sup>, Lannoy D. <sup>1,4</sup>, Vasseur M. <sup>1,4</sup>, Odou P. <sup>1,4</sup>

1: CHU Lille, Institut de pharmacie, Lille, France - 2: Univ. Lille, CHU Lille, Service de Dermatologie, Inserm INFINITE, Lille, France -

3: CHU Lille, Service de Pneumologie et Immuno-allergologie, Lille, France - 4: Univ. Lille, GRITA – Groupe de Recherches sur les formes Injectables et les Technologies Associées, Lille, France

## INTRODUCTION

Hypersensitivity reactions (HSR) for cytotoxic drugs → potentially life-threatening adverse effects

Imputability of a drug for causing HSR → allergological workup :

Skin tests (ST) → - Immediate HSR: Prick Test (PT) and Intradermal test (IDT) (several dilutions)  
→ - Delayed HSR: patch test, PT and IDT (several dilutions)

Extemporaneous, dematerialized, computerized preparation of ST for injectable chemotherapy molecules at our centralized cytotoxic preparation unit (UPCC)

## OBJECTIVE

This study aims to evaluate the impact of the ST preparation activity on exploring HSR to injectable chemotherapy molecules within our UPCC

## MATERIALS & METHODS

Between 01/01/2008 and 31/01/2023

Analysis of Excel® manufacturing sheets for ST preparations (computerization started during the study period)

Computer extraction of ST preparations from Chimio® software and data analysis

### Data collected on Microsoft® Excel® 2013 :

**Demographic data:** Age - Sex & **Pharmaceutical data:** Molecule tested - Number of ST series - Total number of preparations

**Medical data via Patient Medical Record (PMR):** History of HSR - Type of HSR  
ST results - Behavior

## RESULTS

Number of extracted PMR 96 → Number of PMR with sufficient information for analysis 76

**Demographic data:** Patients aged between 26 and 80 (mean age 60 +/- 11.9 years)

Majority of women (57.9%)


**Pharmaceutical data:** 1 patient could receive several series of ST

**136 series of ST** → 113 series of cytotoxics → 50% platinum salts  
→ 23 series of monoclonal antibodies → 22% of Daratumumab and 22% of Nivolumab

**Total of 568 preparations** - - Variable concentrations and number of dilutions for the same molecule

### Medical data:

16 patients with a history of HSR (21%) | Type of HSR : Immediate (60%)  
Delayed (29%)  
Missing information (8%)



## CONCLUSION

Our UPCC has seen an increase in the number of ST prepared for the investigation of HSR to injectable chemotherapies. **Of the 136 series prepared, 86 have been prepared in the last 2 years.** Based on a review of the literature, a thesaurus was developed to standardize preparations. The preparation and performance of ST enabled 51 patients to have the CI to their initial treatment lifted.